Terrence Park
About Terrence Park
Terrence Park is a Senior Scientist in In Vivo Biology at Asher Biotherapeutics, where he has worked since 2019. He previously spent 13 years at Pfizer in the Oncology-Rinat R&D Group and holds degrees in Neurobiology, Physiology, and Behavior from the University of California, Davis, as well as in Computer Science from California State University - East Bay.
Work at Asher Bio
Terrence Park has been serving as a Senior Scientist in In Vivo Biology at Asher Biotherapeutics since 2019. In this role, he focuses on advancing biotherapeutic research and development. His work involves the study of innovative approaches to enhance therapeutic efficacy, particularly in the context of cancer treatment. His expertise in in vivo models contributes to the development of new strategies for immunotherapy.
Previous Experience at Pfizer
Prior to joining Asher Biotherapeutics, Terrence Park worked at Pfizer for 13 years, from 2006 to 2019. He was part of the Oncology-Rinat R&D Group, where he contributed to various oncology research initiatives. His experience at Pfizer provided him with a strong foundation in drug development and research methodologies within the pharmaceutical industry.
Education and Expertise
Terrence Park holds a Bachelor of Science degree in Neurobiology, Physiology, and Behavior from the University of California, Davis, which he completed from 1995 to 2000. He also earned a Bachelor of Science degree in Computer Science from California State University - East Bay, studying from 2001 to 2003. His educational background combines biological sciences with computational skills, enhancing his research capabilities.
Research Contributions
Terrence Park has been actively involved in significant research within the field of immunotherapy. He participated in research presented at the Society for Immunotherapy of Cancer (SITC) in November 2022, focusing on the selective activation of CD8+ T cells through a CD8-targeted IL-2. Additionally, he contributed to studies on engineered cell surface tag-targeted IL-2 and IL-21 aimed at enhancing CAR-T anti-tumor activity.
Involvement in Cancer Research Conferences
In April 2022, Terrence Park participated in research presented at the American Association of Cancer Research (AACR). His work included the selective support of CAR-T cell therapies using cis-targeted IL-2 or IL-21 cytokines. His contributions to these conferences highlight his active engagement in advancing cancer research and therapies.